O'Neill Gilmore Neil 4
4 · Editas Medicine, Inc. · Filed Mar 5, 2024
Insider Transaction Report
Form 4
O'Neill Gilmore Neil
DirectorCEO
Transactions
- Award
Common Stock
2024-03-02+130,700→ 260,869 total - Award
Common Stock
2024-03-02+72,213→ 333,082 total - Award
Common Stock
2024-03-02+72,212→ 405,294 total - Sale
Common Stock
2024-03-05$9.42/sh−77,824$732,884→ 327,470 total - Award
Stock Option (right to buy)
2024-03-02+392,100→ 392,100 totalExercise: $10.53Exp: 2034-03-01→ Common Stock (392,100 underlying)
Footnotes (6)
- [F1]The common stock received by the Reporting Person was in connection with the grant of a restricted stock unit award to the Reporting Person, for no consideration, and which is scheduled to vest over four years with 25% of the units vesting on March 2, 2025 and the remaining 75% of the units scheduled to vest in equal quarterly installments thereafter through March 2, 2028.
- [F2]Reflects the vesting, upon the achievement of a specified research and development milestone, of a portion of a performance-based restricted stock unit award originally granted on June 2, 2022.
- [F3]Reflects the vesting, upon the achievement of a business development milestone, of a portion of a performance-based restricted stock unit award originally granted on June 2, 2022.
- [F4]Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on April 13, 2022, and represents the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units on March 2, 2024. The sale does not represent a discretionary trade by the Reporting Person.
- [F5]This transaction was executed in multiple trades at prices ranging from $9.1036 to $9.4298. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request, to the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.
- [F6]This option was granted on March 2, 2024 and is scheduled to vest over four years in equal monthly installments beginning on April 2, 2024 through March 2, 2028.